Mercury Laboratories Ltd

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook amid mixed financial and valuation metrics. While the company’s recent quarterly performance shows promise, long-term fundamentals and market returns continue to weigh on investor sentiment.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 Mar 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 02 May 2026, providing investors with the latest insights into its performance and outlook.

A sharp decline of 19.41% intraday has dragged Mercury Laboratories Ltd to a fresh 52-week low of Rs 620.55 on 24 Apr 2026, marking a significant setback for the micro-cap pharmaceutical player amid a broadly weak market environment.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 21 April 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 March 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 10 April 2026, providing investors with the latest insights into the company’s performance and outlook.

For the third consecutive session, Mercury Laboratories Ltd has seen its share price decline sharply, culminating in a fresh 52-week low of Rs 700.05 on 30 Mar 2026. This marks an 18.12% drop over the last three days, underscoring persistent selling pressure despite some positive financial indicators.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 Mar 2026. This shift reflects a deterioration in technical indicators alongside persistent fundamental weaknesses, despite some recent positive financial results. The company’s stock price has also suffered a sharp decline, underscoring investor caution amid mixed signals.

Mercury Laboratories Ltd’s share price declined sharply to hit a new 52-week low of Rs.730 on 27 March 2026, marking a significant milestone in the stock’s recent performance. The pharmaceutical company’s shares have experienced heightened volatility and downward pressure amid broader market weakness and company-specific factors.

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators amid mixed financial and valuation metrics. While the company’s recent quarterly performance shows promising growth, long-term fundamentals remain weak, prompting a cautious stance from analysts.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 26 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Mercury Laboratories Ltd has declined to a fresh 52-week low of Rs.770, marking a significant downturn in its stock performance amid broader market weakness and sectoral underperformance. The stock’s fall reflects a combination of subdued long-term growth metrics and recent trading volatility.

Mercury Laboratories Ltd has touched a new 52-week low of Rs.775 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance trends. The stock underperformed its sector and continues to trade below all major moving averages, reflecting ongoing challenges in maintaining upward momentum.

Mercury Laboratories Ltd has touched a new 52-week low of Rs.775 today, marking a significant decline in its stock price amid broader sector underperformance and subdued long-term growth metrics.

Mercury Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 26 Feb 2026. This revision reflects deteriorating technical indicators, subdued financial trends, and persistent valuation concerns despite some recent positive quarterly results. The downgrade highlights growing investor caution amid the company’s ongoing underperformance relative to benchmarks and peers.

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, driven primarily by improvements in technical indicators despite ongoing challenges in long-term fundamentals and valuation metrics. This nuanced shift reflects a cautious optimism amid mixed signals across quality, valuation, financial trends, and technical analysis.

Mercury Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 12 Feb 2026. This revision reflects deteriorating quality metrics, bearish technical indicators, and a subdued financial trend, despite some positive quarterly results. The company’s Mojo Score now stands at 29.0, underscoring significant concerns for investors.